Han Qing, Zheng Bang, Daines Luke, Sheikh Aziz
Department of Social Policy and Intervention, University of Oxford, Oxford OX1 2ER, UK.
Usher Institute, University of Edinburgh, Edinburgh EH16 4UX, UK.
Pathogens. 2022 Feb 19;11(2):269. doi: 10.3390/pathogens11020269.
Emerging evidence has shown that COVID-19 survivors could suffer from persistent symptoms. However, it remains unclear whether these symptoms persist over the longer term. This study aimed to systematically synthesise evidence on post-COVID symptoms persisting for at least 12 months. We searched PubMed and Embase for papers reporting at least one-year follow-up results of COVID-19 survivors published by 6 November 2021. Random-effects meta-analyses were conducted to estimate pooled prevalence of specific post-COVID symptoms. Eighteen papers that reported one-year follow-up data from 8591 COVID-19 survivors were included. Fatigue/weakness (28%, 95% CI: 18-39), dyspnoea (18%, 95% CI: 13-24), arthromyalgia (26%, 95% CI: 8-44), depression (23%, 95% CI: 12-34), anxiety (22%, 95% CI: 15-29), memory loss (19%, 95% CI: 7-31), concentration difficulties (18%, 95% CI: 2-35), and insomnia (12%, 95% CI: 7-17) were the most prevalent symptoms at one-year follow-up. Existing evidence suggested that female patients and those with more severe initial illness were more likely to suffer from the sequelae after one year. This study demonstrated that a sizeable proportion of COVID-19 survivors still experience residual symptoms involving various body systems one year later. There is an urgent need for elucidating the pathophysiologic mechanisms and developing and testing targeted interventions for long-COVID patients.
BMC Infect Dis. 2025-9-3
Cardiol Res. 2025-6-9
Rev Soc Bras Med Trop. 2025-8-8
Biomedicines. 2025-7-1
Health Sci Rep. 2025-7-21
Signal Transduct Target Ther. 2021-10-13
BMJ Glob Health. 2021-9
Int J Infect Dis. 2021-11